Someone ran the numbers and decided enough was enough somewhere in a corporate conference room, probably not all that different from the dozens of beige-carpeted ones PwC consultants pass through each week. PwC employees in the US who use GLP-1 drugs like Ozempic or Mounjaro solely for weight control will no longer have their prescriptions covered by the company’s healthcare plan as of July. They are on their own unless they have been diagnosed with diabetes.
This decision could be interpreted as a dry benefits memo. It’s actually more of a signal flare that other big employers have been waiting for someone to send.
PwC cautiously presented the change, pointing to “rapidly rising costs” and the requirement to maintain coverage that is “sustainable over time.” The company claims that it will keep paying for GLP-1 medications when they are prescribed for diseases like type 2 diabetes, which technically keeps the door open but makes it more limited. However, this change wasn’t exactly perceived as a measured policy change by the employees who learned about it when they went to renew their yearly benefits packages. The Financial Times was informed by a staff member that the decision felt disrespectful to obesity as a diagnosis, pointing out that working long hours at a desk isn’t exactly a formula for maintaining an active lifestyle. Even though it is difficult to dispute the financial reasoning behind the cut, that frustration is understandable.
The figures are truly shocking. According to Blue Cross Blue Shield research, adding GLP-1 drugs to employer-sponsored insurance could result in a 14% increase in premiums. That number ceases to be a percentage point and instead appears as a line item with multiple zeros behind it for a company the size of PwC, which employs tens of thousands of people nationwide. Earlier this year, Blue Cross Blue Shield ceased providing coverage for weight-loss medications for its own staff, citing the expenses as a “unsustainable burden.” The message to corporate clients is pretty clear when the insurer pulls coverage for itself.
PwC’s position is what gives this moment its significance. This isn’t a struggling mid-size business cutting benefits to get through a difficult quarter. This company, which is one of the Big Four, actively seeks out talent and prides itself on being able to draw in and keep some of the best experts in the field. If PwC is drawing a line here, it most likely indicates that internal calculations became so uncomfortable that the financial cost of maintaining the benefit began to outweigh the reputational cost of eliminating it. Other businesses have been observing, doing the same calculations, and waiting for a well-known individual to go first. PwC did just that.
This story has a tension that extends beyond a single decision that benefits everyone. GLP-1 drugs, which were first created to treat diabetes but ended up causing dramatic weight loss, became one of the most significant healthcare stories of the past few years. Demand for these drugs skyrocketed, and pharmaceutical companies found themselves at the center of an almost surreal cultural moment. Celebrities talked about them candidly. Before-and-after posts abound on social media. Companies began discreetly incorporating them into benefit plans, in part because it looked good and in part because they genuinely cared about the health of their workers. The math is ugly, and the bill is about to expire.
It’s difficult to think that this trend will end here, but it’s still unclear how many other businesses will follow PwC’s lead in the upcoming months. Benefits that turn into expectations turn into obligations, and obligations at this cost eventually become unsustainable. The corporate world would obviously prefer not to address the more difficult question, which is whether employers are partially to blame for health issues influenced by the demands of contemporary office work. PwC has addressed the financial query for the time being. We’re still figuring out the rest.
